Riskpilot← Back to searchSign inGet full accessEvodiaBio ApS
APSActiveCVR 42569283Islevdalvej 211Research and experimental development on natural sciences and engineering · NACE 7210Est. 202122 employeeswww.evodiabio.com
Revenue 2024
DKK -10M
+1% vs 2023
EBITDA margin
229.4%
-34% vs 2023
Equity ratio
95.2%
Financial strength
Net profit 2024
DKK -21,1M
-50% vs 2023
| Revenue | DKK -10M | +1% |
| EBITDA | DKK -23M | -34% |
| Net profit | DKK -21,1M | -50% |
| Total assets | DKK 55M | +95% |
| Equity | DKK 52,4M | +122% |
| Employees | 22 | — |
Legal name
EvodiaBio ApS
CVR number
42569283
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
28. juli 2021
Share capital
DKK 137.980
Employees
22 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden og et bestyrelsesmedlem i forening, bestyrelsesformanden og et direktionsmedlem i forening, eller den samlede bestyrelse i forening.
Company purpose
Selskabets formål er at udvikle nye aroma- og smagsstoffer til forskellige formål som inkluderer drikkevarer, fødevarer, parfume og andre anvendelser.
Address
Islevdalvej 211
Email
info@evodiabio.com
Website
www.evodiabio.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | -608 | -2.943 | -9.942 | -10.009 |
| Staff expenses | -522 | -4.124 | -7.239 | -12.947 |
| EBITDA | -1.130 | -7.067 | -17.181 | -22.956 |
| Depreciation & amort. | -0 | -118 | -320 | -1.622 |
| EBIT | -1.130 | -7.186 | -17.501 | -24.577 |
| Net financials | -54 | -263 | 427 | 254 |
| Profit before tax | -1.184 | -7.449 | -17.074 | -24.324 |
| Tax | -157 | -1.144 | -3.017 | -3.217 |
| Net profit | -1.027 | -6.305 | -14.057 | -21.107 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 3.806 | 38.487 | 28.166 | 55.043 |
| Equity | -787 | 37.682 | 23.626 | 52.424 |
| Long-term debt | 4.040 | 0 | 0 | 0 |
| Short-term debt | 553 | 805 | 4.540 | 2.619 |
| Total debt | 4.592 | 805 | 4.540 | 2.619 |
EBITDA margin
-2295555100.0%
This company
15.8%
Market median
-14528829847% vs market
20212024
Equity ratio
95.2%
This company
38.2%
Market median
+149% vs market
20212024
Return on equity
-40.3%
This company
18.4%
Market median
-319% vs market
20212024
Net profit margin
-2110659800.0%
This company
8.1%
Market median
-26057528495% vs market
20212024
Asset turnover
-0.18×
This company
1.12×
Market median
-116% vs market
20212024
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20212024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-07-28 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CB Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
SL Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 15.0% | 15.0% | 2025 | |
Danmarks Eksport- og Investeringsfond | Company | 10.0% | 10.0% | 2025 |
STARFISH BIO ApS | Company | 5.0% | 5.0% | 2025 |
BII Holdings A/S | Company | 5.0% | 5.0% | 2024 |
| Individual | 5.0% | 5.0% | 2025 | |
SDBIO ApS | Company | 5.0% | 5.0% | 2025 |
| Individual | 5.0% | 5.0% | 2024 | |
FormanBiotech Holding ApS | Company | 5.0% | 5.0% | 2025 |
BioInnovation Institute Fonden | Company | 10.0% | 10.0% | 2022 |
| Individual | 5.0% | 5.0% | 2024 | |
| Individual | 5.0% | 5.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of EvodiaBio ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Camilla Benedicte Kloss Fenneberg | Chief Executive Officer | 0 companies |
| Simon Louis Théodore Armand Dusséaux | Chief Executive Officer | 0 companies |
| Lauri Johannes Reuter | Board of Directors | 0 companies |
| Sotirios Kampranis | Board of Directors | 0 companies |
| Anne Françoise Véronique Cabotin | Board of Directors | 0 companies |
| Flemming Besenbacher | Board of Directors | 0 companies |
| Andreas Helmut Fibig | Board of Directors | 0 companies |
| Johan Bitsch Nielsen | Board of Directors | 0 companies |
| Kyle Bjorn Teamey | Board of Directors | 0 companies |
| Bart Van Hooland | Board of Directors | 0 companies |
| Victor Forman | Board of Directors | 0 companies |